Clinical Trial Update: A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports termination of the study evaluating BGB-3245 (brimarafenib) in combination with panitumumab for advanced or metastatic RAS-mut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BGB-3245 (Brimarafenib) (brimarafenib)
• Panitumumab (panitumumab)

Snippet

Sponsor: MapKure, LLC | Conditions: Colorectal Cancer, Pancreatic Ductal Cancer | Phase 1 | Status: TERMINATED